Products Categories
CAS No.: | 6912-63-6 |
---|---|
Name: | 1-Sedrin |
Molecular Structure: | |
Formula: | C10H15NO |
Molecular Weight: | 165.235 |
Synonyms: | 1-Hydroxy-2-methylamino-1-phenylpropane;(1R,2S)-2-(Methylamino)-1-phenylpropan-1-ol;(-)-alpha-(1-Methylaminoethyl)benzyl alcohol;Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, (alphaR)-;Benzenemethanol, alpha-(1-(methylamino)ethyl)-, (-)-;alpha-Hydroxy-beta-methyl amine propylbenzene;Ephedrine;2-Methylamino-1-phenyl-1-propanol;1-Phenyl-2-methylaminopropanol;Ephedremal;1-Phenyl-1-hydroxy-2-methylaminopropane; |
EINECS: | 206-080-5 |
Density: | 1.015 g/cm3 |
Melting Point: | 37-39 °C |
Boiling Point: | 255 °C at 760 mmHg |
Flash Point: | 85.6 °C |
Solubility: | 63.4 mg/L in water at 25 ºC |
Appearance: | white crystals or powder |
Hazard Symbols: | Xn |
Risk Codes: | 22 |
Safety: | 22-25 |
The (L)-Ephedrine, with the CAS registry number 6912-63-6, is also known as 1-Phenyl-1-hydroxy-2-methylaminopropane. It belongs to the product categories of Miscellaneous Natural Products; Chiral. Its EINECS number is 206-080-5. This chemical's molecular formula is C10H15NO and molecular weight is 165.23. What's more, its systematic name is (1R,2S)-2-(methylamino)-1-phenylpropan-1-ol. Its classification codes are: (1)Adrenergic agents; (2)Autonomic Agents; (3)Bronchodilator; (4)Cardiovascular Agents; (5)Central Nervous System Agents; (6)Central nervous system stimulants; (7)Drug / Therapeutic Agent; (8)Human Data; (9)Natural Product; (10)Neurotransmitter Agents; (11)Peripheral Nervous System Agents; (12)Reproductive Effect; (13)Sympathomimetics; (14)Vasoconstrictor agents. It should be sealed and stored in a brown glass container placed in a dry place with a low temperature. What's more, it should be protected from oxidants, water and light. It is a sympathomimetic amine commonly used as a stimulant, appetite suppressant, concentration aid, decongestant, and to treat hypotension associated with anaesthesia.
Physical properties of (L)-Ephedrine are: (1)ACD/LogP: 1.05; (2)# of Rule of 5 Violations: 0; (3)ACD/LogD (pH 5.5): -1.99; (4)ACD/LogD (pH 7.4): -0.96; (5)ACD/BCF (pH 5.5): 1; (6)ACD/BCF (pH 7.4): 1; (7)ACD/KOC (pH 5.5): 1; (8)ACD/KOC (pH 7.4): 1; (9)#H bond acceptors: 2; (10)#H bond donors: 2; (11)#Freely Rotating Bonds: 4; (12)Polar Surface Area: 12.47 Å2; (13)Index of Refraction: 1.528; (14)Molar Refractivity: 50.15 cm3; (15)Molar Volume: 162.7 cm3; (16)Polarizability: 19.88×10-24cm3; (17)Surface Tension: 38 dyne/cm; (18)Density: 1.015 g/cm3; (19)Flash Point: 85.6 °C; (20)Enthalpy of Vaporization: 52.03 kJ/mol; (21)Boiling Point: 255 °C at 760 mmHg; (22)Vapour Pressure: 0.00865 mmHg at 25°C.
Preparation of (L)-Ephedrine: this chemical can be prepared by (1R,2S)-2-[(ethoxycarbonyl)amino]-1-phenyl-1-propanol at the temperature of 60 °C. This reaction will need reagent LiAlH4 and solvent tetrahydrofuran with the reaction time of 1.5 hours. The yield is about 80%.
Uses of (L)-Ephedrine: it can be used to produce (1R,2S)-N-benzyl-(-)-ephedrine at the ambient temperature. It will need reagent pyridine with the reaction time of 72 hours. The yield is about 60%.
When you are using this chemical, please be cautious about it as the following:
It is harmful if swallowed. You should not breathe dust. When using it, you must avoid contacting with eyes.
You can still convert the following datas into molecular structure:
(1)Canonical SMILES: CC(C(C1=CC=CC=C1)O)NC
(2)Isomeric SMILES: C[C@@H]([C@@H](C1=CC=CC=C1)O)NC
(3)InChI: InChI=1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10-/m0/s1
(4)InChIKey: KWGRBVOPPLSCSI-WPRPVWTQSA-N
The toxicity data is as follows:
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
bird - wild | LD50 | oral | 562mg/kg (562mg/kg) | Archives of Environmental Contamination and Toxicology. Vol. 12, Pg. 355, 1983. | |
cat | LDLo | intravenous | 60mg/kg (60mg/kg) | Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 120, Pg. 189, 1927. | |
dog | LDLo | intravenous | 70mg/kg (70mg/kg) | Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 120, Pg. 189, 1927. | |
frog | LDLo | parenteral | 530mg/kg (530mg/kg) | Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 120, Pg. 189, 1927. | |
guinea pig | LD50 | subcutaneous | 420mg/kg (420mg/kg) | Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 169, Pg. 114, 1933. | |
man | LDLo | unreported | 9mg/kg (9mg/kg) | "Poisoning; Toxicology, Symptoms, Treatments," 2nd ed., Arena, J.M., Springfield, IL, C.C. Thomas, 1970Vol. 2, Pg. 73, 1970. | |
mouse | LD50 | intraperitoneal | 350mg/kg (350mg/kg) | BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) | Pharmaceutical Chemistry Journal Vol. 3, Pg. 203, 1969. |
mouse | LD50 | intravenous | 74mg/kg (74mg/kg) | BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) | Acta Pharmacologica et Toxicologica. Vol. 38, Pg. 474, 1976. |
mouse | LD50 | oral | 689mg/kg (689mg/kg) | Japanese Journal of Toxicology. Vol. 4, Pg. 143, 1991. | |
mouse | LD50 | parenteral | 170mg/kg (170mg/kg) | Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 195, Pg. 647, 1940. | |
mouse | LD50 | subcutaneous | 132mg/kg (132mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 3, Pg. 328, 1953. | |
mouse | LDLo | unreported | 600mg/kg (600mg/kg) | AUTONOMIC NERVOUS SYSTEM: SYMPATHOMIMETIC | Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 153, Pg. 161, 1930. |
rabbit | LDLo | intramuscular | 340mg/kg (340mg/kg) | CARDIAC: OTHER CHANGES LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 120, Pg. 189, 1927. |
rabbit | LDLo | intraperitoneal | 310mg/kg (310mg/kg) | CARDIAC: OTHER CHANGES LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 120, Pg. 189, 1927. |
rabbit | LDLo | intravenous | 50mg/kg (50mg/kg) | CARDIAC: OTHER CHANGES LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 120, Pg. 189, 1927. |
rabbit | LDLo | oral | 590mg/kg (590mg/kg) | CARDIAC: OTHER CHANGES LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 120, Pg. 189, 1927. |
rabbit | LDLo | subcutaneous | 320mg/kg (320mg/kg) | CARDIAC: OTHER CHANGES LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 120, Pg. 189, 1927. |
rat | LD50 | oral | 600mg/kg (600mg/kg) | "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 341, 1972. | |
rat | LD50 | subcutaneous | 300mg/kg (300mg/kg) | Archives Internationales de Pharmacodynamie et de Therapie. Vol. 68, Pg. 339, 1942. | |
rat | LDLo | intraperitoneal | 150mg/kg (150mg/kg) | Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 195, Pg. 647, 1940. | |
rat | LDLo | intravenous | 130mg/kg (130mg/kg) | Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 120, Pg. 189, 1927. |